VALUE OF UNIVERSAL CHILDHOOD VARICELLA VACCINATION IN SLOVENIA
Abstract
Background. In 1974 effective and safe vaccine against varicella was developed. Vaccination is recomended for universal childhood immunisation in some of west European countries and in the United States. The aim of the study was to perform economic analysis of universal childhood vaccination against varicella in Slovenia.
Methods. We examined hypothetical birth cohort of 5800 persons followed from birth to their 30th birthday and calculated the cost-benefit ratio for varicella vaccination program. We assumed that one dose of vaccine would be given to 15-monthold children along with measles, mumps and rubella vaccination. It was also assumed that 95% of children would be vaccinated, that vaccine efficacy would be 90%, that vaccine induced immunity would be lifelong and that the program would have no effect on either the incidence rate or severity of herpes zoster. For both disease and vaccine we measured the direct medical cost and indirect cost.
Results. Indirect cost represented major part compared to medical cost. The benefit to cost ratio was 0.89.
Conclusions. Considering major assumptions in this analysis, there is no financial benefits from vaccinating all children against varicella in our country.
Downloads
References
Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis J 1984; 3: 505–9.
Kraigher A, Hočevar-Grom A, Klaus I et al. Epidemiološko spremljanje nalezljivih bolezni v Sloveniji v letu 1998. Zdrav Var 1999; 38: Suppl 4: 3–80.
Jaeggi A, Zurbruegg RP, Aebi C. Complications of varicella in a defined central European population. Arch Dis Child 1998; 79: 472–7.
Gershon AA, Takahashi M, White CJ. Varicella vaccine. In: Plotkin SA, Orenstein WA. Vaccines. Philadelphia: Saunders, 1999: 475–507.
Tan AYS, Connett CJ, Connett GJ. Use of a reformulated Oka strain varicella vaccine in healthy children. Eur J Pediatr 1996; 155: 706–11.
Handysides S. The United States recommends immunisation against varicella for children. Should Europe? URL: http//www.eurosurv.org/weeknews.htm.
Domingo JD, Ridao M, Latour J, Ballester A, Morant A. A cost-benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17: 1306–11.
Maharshak N, Somekh E. Hospitalization for varicella in central Israel. Acta Paediatr 1999; 88: 1279–83.
Zakotnik B, Čižman M. Nekatera novejša cepiva in indikacije za njihovo uporabo. In: Čižman M, Strle F eds. Infektološki simpozij, Ljubljana 1999. Med Razgl 1999; 38: Suppl 2: 187–207.
CDC. Varicella-related deaths among children – United States 1997. MMWR 1997; 46: 409–12.
Preblud SR. Varicella: complications and costs. Pediatrics 1986; 78: Suppl 4: 728–35.
Fornaro P, Gandini P, Marin M et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J 1999; 18: 414–9.
Law B, Fitzsimon C, Ford-Jones L, McCormick J, Riviere M. Cost of chickenpox in Canada: part 2. Cost of complicated cases and total economic impact. Pediatrics 1999; 104: 7–14.
Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142–51.
Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994; 271: 375–81.
Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994; 124: 869–74.
Preblud SR, Orenstein WA, Bart KJ, Koplan KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985; 61: Suppl 4: 17–22.
Beutels P, Clara R, Tormans G, Doorslaer EV, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infec Dis 1996; 174: Suppl 3: 335–41.
Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000; 18: 407–15.
Program imunoprofilakse in kemoprofilakse za leto 2001. Ur. l. RS št. 18/01: 1776–88.
Pokorn M, Čižman M. Pregled ekonomske upravičenosti cepljenja proti Haemophilusu influenzae tip B. In: Čižman M, Strle F eds. Infektološki simpozij 1999. Ljubljana: Med Razgl 1999; 38: Suppl 2: 209–16.
Zarnke KB, Levine MAH, Obrien BJ. Cost-benefit analyses in the health care literature. J Clin Epidemiol 1997; 50: 813–22.
Statistični letopis Republike Slovenije. Leto 1995 do 1999. Ljubljana: Statistični urad Republike Slovenije, 2000: 1–20.
Teržan M. Bolniški stalež. Med Razgl 1998; 37: 399–411.
Saražin-Klemenčič K, Švab I. O ceni človeškega življenja. Zdrav Vestn 1998; 67: 643–5.
Rogač M, Teržan M, Markota M. Prenova zunajbolnišnične zdravstvene statistike. Zdrav Vestn 1996; 68: 31–2.
Oxman MN. Varicella. In: Braude AI, Davis CE, Fierer J eds. Infectious diseases and medical microbiology. Philadelphia: Saunders, 1986: 1392– 406.
Plotkin SA. Clinical and pathogenetic aspect of varicella-zoster. Postgrad Med J 1986; 61: Suppl 4: 7–14.
Hull D, Johnston DI. Essential paediatrics. New York: Churchill Livingstone, 1987: 164–5.
CDC. Varicella-zoster immune globulin for the prevention of chickenpox. MMWR 1984; 33: 84–99.
Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am 1996; 10: 617–29.
Gershon AA, Steinberg S, Brunell PA. Zoster immune globulin-a further assessment. N Engl J Med 1974; 290: 243–3.
Asanao Y, Suga S, Yoshikawa T et al. Experience and reason; twenty year follow up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994; 94: 524–6.
Hardy I, Gershon AA., Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N Engl J Med 1991; 325: 1545–50.
Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long term results of vaccination. Pediatrics 1997; 99: 35–9.
Miljevič J, Bensa B, Gregorc C, Kristl M, Krivec D. Vrednotenje prometnih nesreč na cestah v Republiki Sloveniji. Ljubljana: Omega consult d.o.o., 2000: 36–6.
American academy of pediatrics. Committee on infectious diseases. Varicella vaccine update. Pediatrics 2000; 105: 136–41.
Advisory committee on immunization practices. Prevention of varicella. MMWR 1999; 48: 1–5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
